)
Visual
test
SpringWorks Therapeutics
SpringWorks Therapeutics (SWTX) investor relations material
SpringWorks Therapeutics has been delisted
SpringWorks Therapeutics Q1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2025 earnings summary8 May, 2025
Executive summary
SpringWorks Therapeutics is a commercial-stage biopharma focused on rare diseases and oncology, with two FDA-approved products: OGSIVEO and GOMEKLI, and a pipeline of clinical and preclinical candidates.
OGSIVEO (nirogacestat) is approved for adult desmoid tumors; GOMEKLI (mirdametinib) is approved for NF1-associated plexiform neurofibromas in adults and children.
On April 27, 2025, SpringWorks entered into a merger agreement to be acquired by Merck KGaA, Darmstadt, Germany, for $47.00 per share in cash, pending customary closing conditions.
Financial highlights
Net product revenue for Q1 2025 was $49.1 million, up 134% year-over-year from $21.0 million in Q1 2024, driven by OGSIVEO and GOMEKLI launches.
Net loss for Q1 2025 was $83.2 million, compared to $87.4 million in Q1 2024, a 5% improvement.
Cash, cash equivalents, and marketable securities totaled $382.7 million as of March 31, 2025, down from $461.9 million at year-end 2024.
Operating expenses increased to $129.6 million in Q1 2025 from $114.9 million in Q1 2024, mainly due to higher SG&A costs for commercialization.
Net cash used in operating activities was $68.8 million for Q1 2025, compared to $78.9 million in Q1 2024.
Outlook and guidance
Management expects current liquidity to fund operations for at least twelve months from the reporting date.
Profitability is anticipated in the first half of 2026, contingent on continued commercial success of OGSIVEO and GOMEKLI.
Pre-commercial preparations for OGSIVEO and GOMEKLI are underway in Europe, with regulatory decisions expected in 2025.
What is the status of the MAA for nirogacestat?
What are the expected wind-down costs for MapKure?
What are the restrictions on business activities?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SpringWorks Therapeutics
- Q2 revenue hit $59.7M, OGSIVEO led sales, net loss narrowed, mirdametinib NDA submitted.SWTX
Q2 20242 Feb 2026 - Ogsiveo and mirdametinib drive growth, with strong adoption, market confidence, and pipeline momentum.SWTXGoldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026
- OGSIVEO revenue up 23% in Q3; mirdametinib advanced in review, narrowing net loss.SWTXQ3 202414 Jan 2026
- Ogsiveo surpasses forecasts, with strong U.S. growth, new formulations, and European launch ahead.SWTXGuggenheim’s Inaugural Healthcare Innovation Conference14 Jan 2026
- Rapid market adoption and pipeline progress signal major growth ahead.SWTXJefferies London Healthcare Conference 202413 Jan 2026
- Ogsiveo and mirtametinib launches drive growth, with strong data and expanding global reach.SWTX7th Annual Evercore ISI HealthCONx Healthcare Conference12 Jan 2026
- OGSIVEO's rapid adoption and mirdametinib's pending approval drive growth and profitability.SWTX43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026
- First-in-class oncology therapies OGSIVEO and GOMEKLI fuel growth, global expansion, and pipeline momentum.SWTXCorporate Presentation4 Jul 2025
- OGSIVEO and mirdametinib drive growth as SpringWorks advances a robust, diversified oncology pipeline.SWTXCorporate Presentation13 Jun 2025
SpringWorks Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage